AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06053606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)
Description: first applications in LSPV and RSPV are done with 31 mm balloon
Study NCT05950867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ECG + echocardiography
Description: Electrocardiogram and echocardiography
Study NCT05950867 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Answering questionnaires
Description: Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
Study NCT06125925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Description: Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
Study NCT06125925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
Study NCT06445244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-ketoglutarate supplied as 1000mg capsule
Description: AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
Study NCT05160168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THE-630
Description: Oral THE-630 administered once daily in a continuous regimen
Study NCT05769855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 380mg
Study NCT05769855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine HCl
Description: ropivacaine HCl 75mg.
Study NCT05769855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Physiological Solution
Description: Sodium Chloride Physiological Solution 20ml
Study NCT05231928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Laser Iridoplasty
Description: Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution.
Study NCT06445244 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral: Lifestyle modification
Description: Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
Study NCT06445244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Lifestyle modification
Description: Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
Study NCT05473416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie back extension exercise
Description: McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
Study NCT05473416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates pelvic tilt exercise
Description: Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
Study NCT05473416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline treatment
Description: Postural guidelines + proper lifting technique + stretch break Rest
Study NCT05070559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)
Study NCT05070559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston Technique Group
Description: Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)
Study NCT06217211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Remolacha
Description: BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
Study NCT06217211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Remolacha
Description: BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
Study NCT06359548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peeled ILM Reposition
Description: The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required.
Study NCT06359548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM Peeling
Description: The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
Study NCT06515457 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eye Empower
Description: Participants will take three capsules of the Eye Empower supplement daily for three weeks.
Study NCT06447389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: retraction cordu (SURE-CORD®PLUS)
Description: The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
Study NCT05089461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
Study NCT05587699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 45mg(Multiple dose)
Description: 1 Injection/3 Month, 3 times Injections
Study NCT05587699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 45mg
Description: Single Injection
Study NCT05587699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 55mg(Multiple dose)
Description: 1 Injection/3 Month, 3 times Injections
Study NCT05587699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-843 A 55mg
Description: Single Injection
Study NCT05587699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-843-R
Description: 0.5mg/day, 9 Month
Study NCT05459701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg once daily for 24 weeks.
Study NCT05459701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06215391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d printed mask
Description: * Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted.
Study NCT05461053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX 4 Topical Cream
Description: The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
Study NCT04915261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lenient Arm Restriction
Description: The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
Study NCT04915261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strict Arm Restriction
Description: The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
Study NCT05067114 — intervention group
Intervention type: DEVICE
Intervention: Screening, detection and referral for atrial fibrillation
Description: In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
Study NCT06488014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plan block (ESP)
Description: In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9.
Study NCT06488014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9.
Study NCT04830176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dentifrice
Description: use of dentifrices for brushing
Study NCT05206682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin will be used to postpone period after vaginal repair.
Study NCT04988542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Circadian Wellness sleep SL strip
Description: Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
Study NCT04988542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Circadian Wellness sleep SL strip
Description: Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
Study NCT04427904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 1:200 000 epinephrine
Description: Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Study NCT04427904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% with 1:100 000 epinephrine
Description: Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Study NCT06355414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Drug administration under supportive conditions
Study NCT06192043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Psychoeducational Intervention
Description: Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
Study NCT04931524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbon-14-[14C]-ANG-3777
Description: Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
Study NCT06355414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Drug administration under supportive conditions
Study NCT05126810 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04723472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime containing bismuth quadruple treatment
Description: Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days.
Study NCT04723472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic bismuth quadruple treatment
Description: Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days.
Study NCT05995678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-Home-SP
Description: This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
Study NCT05995678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program
Description: Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
Study NCT05995678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transition Assistance Program
Description: Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
Study NCT05651789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
Study NCT05651789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
Study NCT05054478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab added to induction, first consolidation and second consolidation
Study NCT05995678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA Solid Start
Description: VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
Study NCT05995678 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Solid Start
Description: VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
Study NCT05562128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active forest therapy
Description: Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
Study NCT05562128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive forest therapy
Description: Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.